Tech Company Financing Transactions

Viamet Pharmaceuticals Funding Round

On 7/7/2009, Viamet Pharmaceuticals raised $18 million in Series B funding from Novartis Venture Fund, Astellas Venture Capital and Hatteras Venture Partners.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

4505 Emperor Blvd. 300
Durham, NC 27703
USA

Phone

(919) 467-8539

Website

www.viamet.com

Email Address

Not Recorded

Overview

Viamet Pharmaceuticals discovers and develops best-in-class inhibitors of validated metalloenzymes via an innovative and proprietary metal-binding approach, our Metallophile Technology.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Robert Schotzinger

        

Chief Medical Officer

Oren Cohen

        

VP - Product Management

Thorsten Degenhardt

        

Browse more venture capital transactions:

Prev: 7/6/2009: Savana BPM venture capital transaction
Next: 7/7/2009: People Capital venture capital transaction

Share this article

About Our VC Transactions Data

Our team works diligently to report on all VC transactions involving tech companies. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary